Peptide PET tracer offers promising early breast-cancer imaging results

What happened?

A study published in the Journal of Nuclear Medicine describes a gallium-68-labelled dimeric cyclic peptide, [68Ga]Ga-TDN1, designed to bind nectin-4. This protein is found at increased levels in several types of cancer, making it a potential target for molecular imaging.

The researchers first tested how selectively the tracer bound to its target in laboratory and animal models. They then assessed it in a small first-in-human pilot involving six people with breast cancer, comparing scans with conventional FDG PET/CT. In this early evaluation, the tracer showed comparable imaging for primary tumours and most lymph-node metastases, with higher uptake and improved detection of some bone and liver lesions in selected patients.

This was an imaging feasibility study, not a trial demonstrating better cancer outcomes. Six participants are far too few to establish routine clinical usefulness. Further studies must clarify how consistently the technique performs and when it adds value to existing scans.

Read the original evidence

Explore the primary announcement or study behind this story.